MRTX — Mirati Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Annual cashflow statement for Mirati Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -98.4 | -213 | -358 | -582 | -741 |
| Depreciation | |||||
| Non-Cash Items | 14.5 | 52.1 | 69.5 | 126 | 177 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 13.6 | 13.2 | 16.2 | 65.6 | -10.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -70.1 | -148 | -272 | -389 | -571 |
| Capital Expenditures | -0.122 | -1.55 | -4.37 | -9.79 | -4.85 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -146 | -175 | -135 | -579 | 231 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -146 | -176 | -140 | -589 | 226 |
| Financing Cash Flow Items | — | 1.05 | 0.041 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 141 | 338 | 1,251 | 505 | 167 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -75 | 14.2 | 839 | -472 | -178 |